Akèy › Tit travay › Scientist III
Scientist III: Salè H-1B
168 aplikasyon kondisyon travay te itilize tit travay Scientist III. Salè baz medyàn ofri $95,000; mwatye mitan $75,148–$110,000.
Demann (LCA)168
Salè medyan ofri$95,000
Mwatye salè yo$75,148–$110,000
10yèm–90yèm pousantaj$62,400–$127,645
Avoka imigrasyon, rekritè oswa anplwayè? Mete sèvis ou an tèt paj sa a — $99 pou 30 jou →
Anplwayè yo
| Anplwayè | LCA | Salè medyan |
|---|
| University of Wisconsin System | 19 | $100,000 |
| Eurofins Lancaster Laboratories Professional Scientific Services, LLC | 11 | $60,000 |
| PPD Development, L.P. | 11 | $76,690 |
| Primera Analytical Solutions Corporation | 9 | $95,000 |
| University Corporation for Atmospheric Research | 9 | $99,225 |
| University of Kentucky | 8 | $70,000 |
| Tufts University | 7 | $80,000 |
| Eurofins Professional Scientific Services Mid-Atlantic, LLC. | 7 | $54,678 |
| Eurofins Professional Scientific Services New England, LLC. | 6 | $67,600 |
| The University of Alabama at Birmingham | 5 | $101,404 |
| Pace Analytical Services LLC | 5 | $98,134 |
| BioAgilytix Labs, LLC | 4 | $125,000 |
| Allen Institute | 4 | $120,439 |
| Pharmaron (Boston) Lab Services, LLC | 4 | $93,891 |
| The Fountain Group, LLC | 4 | $116,480 |
| E Ink Corporation | 3 | $108,535 |
| University of Mississippi Medical Center | 3 | $69,260 |
| Katalyst Healthcares & Life Sciences Inc. | 3 | $85,842 |
| Univ of WI System | 2 | $84,228 |
| Contract Pharmacal Corp | 2 | $93,700 |
| Boehringer Ingelheim Animal Health USA, Inc. | 2 | $99,499 |
| Entegris, Inc. | 2 | $110,000 |
| Imugene (USA) Inc. | 2 | $134,000 |
| Thermo Fisher Scientific Inc. | 2 | $101,816 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $106,166 |
| Archer Daniels Midland Company | 2 | $90,000 |
| ProBio Inc. | 2 | $105,000 |
| Exelixis, Inc | 2 | $126,244 |
| Novelstar Pharmaceuticals Inc | 1 | $88,155 |
| Rani Therapeutics, LLC | 1 | $138,653 |
| Zymergen Inc. | 1 | $160,000 |
| DiaCarta, Inc. | 1 | $84,282 |
| Ocular Therapeutix, Inc. | 1 | $100,000 |
| Axbio, Inc. | 1 | $130,000 |
| Organovo, Inc. | 1 | — |
| Industrial Microbes, Inc. | 1 | $116,200 |
| University of Maine | 1 | $58,349 |
| GSI Environmental Inc. | 1 | $87,858 |
| Triad National Security, LLC | 1 | $173,260 |
| Sovereign Technologies, LLC | 1 | $93,600 |
| XenoBiotic Laboratories, Inc., a div. of WuXi | 1 | $95,000 |
| Pyramid Consulting, Inc. | 1 | $97,698 |
| Shattuck Labs, Inc. | 1 | $115,000 |
| BASF Corporation | 1 | $103,000 |
| Sangamo Therapeutics, Inc. | 1 | $148,997 |
| WuXi AppTec Sales, LLC | 1 | $100,000 |
| Actavis Laboratories FL, Inc. | 1 | $152,117 |
| Synthetic Design Lab, Inc. | 1 | $120,000 |
| Celldex Therapeutics | 1 | $125,000 |
| Avance Biosciences, Inc. | 1 | $90,000 |
| Element Materials Technology Santa Clara Inc. | 1 | $119,789 |
| Quantitative Biosciences, Inc. | 1 | $120,016 |
| Granules Pharmaceuticals Inc. | 1 | $85,000 |
| Arranta Bio MA LLC | 1 | $148,270 |
Pa nivo salè
| Nivo revni | Salè medyan |
|---|
| Nivo I (antre) | $84,897 |
| Nivo II (kalifye) | $93,700 |
| Nivo III (eksperyans) | $98,280 |
| Nivo IV (plen kompetans) | $125,000 |
Depatman Travay la etabli kat nivo salè prevanlan pou chak okipasyon ak zòn, soti nan Nivo I (antre) rive nan Nivo IV (plen kompetans). Anplwayè a chwazi nivo ki koresponn ak kondisyon travay la.
Pa ane fiskal
| Ane fiskal | LCA | Salè medyan |
|---|
| FY2023 | 27 | $105,000 |
| FY2024 | 39 | $87,858 |
| FY2025 | 39 | $96,408 |
| FY2026 | 48 | $98,740 |
Vil yo
- Madison, WI21
- Cranbury, NJ11
- Middleton, WI11
- Malvern, PA10
- Lexington, KY8
- Cambridge, MA7
- Durham, NC6
- Boston, MA6
- Birmingham, AL5
- Seattle, WA4
- Woburn, MA4
- Billerica, MA4
- Boulder, CO4
- Greenbelt, MD4
- West Point, PA4
- Alameda, CA3
- Spring House, PA3
- Jackson, MS3
- Medford, MA3
- Lebanon, NJ3
- Hauppauge, NY2
- North Brunswick, NJ2
- Bedford, MA2
- San Diego, CA2
- Houston, TX2
- North Chicago, IL2
- Ridgefield, CT2
- Decatur, IL2
- Pennington, NJ2
- Lexington, MA2
Salè yo se fen ki pi ba nan salè yo ofri sou chak aplikasyon, konvèti nan yon montan anyèl; estatistik yo itilize sèlman aplikasyon tan plen sètifye. Yon LCA pa yon apwobasyon visa epi yon sèl LCA ka kouvri plizyè pozisyon. Sous: Depatman Travay Etazini, Done Divulgasyon LCA OFLC, ane fiskal 2023–2026 (dènye desizyon Jun 30, 2026).